We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
Cap. Flow
+$76.2M
Cap. Flow %
1.6%
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$190M
2
INSM icon
Insmed
INSM
+$168M
3
GILD icon
Gilead Sciences
GILD
+$130M
4
UTHR icon
United Therapeutics
UTHR
+$105M
5
BBIO icon
BridgeBio Pharma
BBIO
+$81.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$121M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.6M
3
RVMD icon
Revolution Medicines
RVMD
+$72.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$63.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Technology 0.03%
3 Communication Services 0.01%
4 Consumer Discretionary 0.01%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STE icon
51
Steris
STE
$22.7B
$21M 0.44%
99,877
-1
-0% -$214
SYRE icon
52
Spyre Therapeutics
SYRE
$9.09B
$20.4M 0.43%
+229,931
New +$16.8M
COAG
53
Hemab Therapeutics
COAG
$2.56B
$20.2M 0.43%
+550,000
New +$15.2M
PODD icon
54
Insulet
PODD
$9.98B
$19.4M 0.41%
127,498
-36,158
-22% -$6.02M
CI icon
55
Cigna
CI
$74.5B
$18.3M 0.39%
66,500
-31,763
-32% -$8.97M
GKOS icon
56
Glaukos
GKOS
$11B
$18M 0.38%
128,667
-17,036
-12% -$2.16M
CVS icon
57
CVS Health
CVS
$124B
$17.5M 0.37%
169,366
+80,003
+90% +$7.14M
BDX icon
58
Becton Dickinson
BDX
$49.9B
$16.6M 0.35%
109,729
-12,158
-10% -$1.82M
GEHC icon
59
GE HealthCare
GEHC
$33.3B
$16.2M 0.34%
252,744
-164,143
-39% -$10.8M
LIVN icon
60
LivaNova
LIVN
$4.52B
$16.1M 0.34%
195,621
+9,436
+5% +$667K
CNC icon
61
Centene
CNC
$33.3B
$14.7M 0.31%
228,865
-32,201
-12% -$1.72M
MRK icon
62
Merck
MRK
$335B
$14.5M 0.31%
113,061
-93,530
-45% -$10.9M
COO icon
63
Cooper Companies
COO
$14.9B
$14.1M 0.3%
197,135
-75,049
-28% -$4.91M
PBLS
64
Parabilis Medicines Inc
PBLS
$4.55B
$13.7M 0.29%
+500,000
New +$13.8M
TEVA icon
65
Teva Pharmaceuticals
TEVA
$42.6B
$11.7M 0.25%
345,899
+95,817
+38% +$3.19M
GMED icon
66
Globus Medical
GMED
$11.5B
$11.5M 0.24%
146,108
-101,153
-41% -$8.6M
PRCT icon
67
Procept Biorobotics
PRCT
$1.24B
$11.3M 0.24%
502,286
– –
ZBH icon
68
Zimmer Biomet
ZBH
$19.2B
$10.9M 0.23%
126,707
-28,864
-19% -$2.53M
VEEV icon
69
Veeva Systems
VEEV
$40B
$10.5M 0.22%
59,347
+2,830
+5% +$467K
ABBV icon
70
AbbVie
ABBV
$442B
$10.2M 0.21%
40,476
-53,091
-57% -$11.4M
TXG icon
71
10x Genomics
TXG
$7.37B
$10M 0.21%
261,470
-68,022
-21% -$1.78M
HCA icon
72
HCA Healthcare
HCA
$88B
$9.26M 0.19%
23,750
-14,015
-37% -$5.93M
AURA icon
73
Aura Biosciences
AURA
$790M
$8.28M 0.17%
+1,166,667
New +$8.35M
MCK icon
74
McKesson
MCK
$101B
$7.27M 0.15%
9,625
-12,727
-57% -$10.1M
THC icon
75
Tenet Healthcare
THC
$21.6B
$7.27M 0.15%
38,868
+599
+2% +$110K
1 2
3
4 5

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Bellevue Group's Q2 2026 Portfolio in Review

As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

  • Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
  • Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
  • Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
  • Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
  • Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.